Results 271 to 280 of about 3,067,072 (318)

Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases

International Immunopharmacology, 2023
JAK kinase includes four family members: JAK1, JAK2, JAK3, and TYK2. It forms the JAK-STAT pathway with signal transmitters and activators of subscription (STAT).
Lianbao Ye
exaly   +2 more sources

JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review

Expert Review of Clinical Pharmacology, 2023
Introduction Numerous cutaneous dermatoses mediated by cytokines depend on the JAK STAT pathway for intracellular signaling. JAK inhibitors form a useful therapeutic approach in treating these conditions. The literature on effectiveness of JAK inhibitors
Aishwarya Muddebihal, Ananta Khurana, Kabir Sardana   +2 more
exaly   +2 more sources

Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders

Actas Dermo-sifiliográficas, 2023
JAK inhibitors target specific inflammatory cytokines involved in various inflammatory diseases. Four molecules have been approved for dermatological use: upadacitinib, baricitinib, abrocitinib and topical ruxolitinib.
Constanza Riquelme-Mc Loughlin
exaly   +2 more sources

JAK inhibitors and systemic sclerosis: A systematic review of the literature

Autoimmunity Reviews, 2022
BACKGROUND Systemic sclerosis (SSc) is a systemic autoimmune disease with heterogeneous clinical presentation and prognosis. JAK inhibitors reduced cutaneous and pulmonary fibrosis in mice models of SSc. Clinical data regarding the efficacy and safety of
Thomas Moulinet, Roland Jaussaud, Paul Decker   +2 more
exaly   +2 more sources

Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.

JAMA dermatology, 2023
Importance Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US Food and Drug Administration (FDA) boxed ...
Jenne P Ingrassia, M. Maqsood, J. Gelfand, Brittany Weber, S. Bangalore, K. L. Lo Sicco, Michael S. Garshick   +6 more
semanticscholar   +1 more source

Selective JAK Inhibitors

Future Medicinal Chemistry, 2014
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock, Eugene Guorong, Yang, Yuyi, Chu-Farseeva, Lianbin, Yao   +3 more
openaire   +2 more sources

Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases

JAMA Network Open
Key Points Question What are the comparative safety profiles of Janus kinase (JAK) inhibitors vs tumor necrosis factor (TNF) antagonists in patients with immune-mediated inflammatory diseases (IMIDs)?
V. Solitano, Dhruv Ahuja, Han Hee Lee, Ritu Gaikwad, Kuan-Hung Yeh, A. Facciorusso, Abha G. Singh, Christopher Ma, Ashwin N. Ananthakrishnan, Yuhong Yuan, Namrata Singh, V. Jairath, Siddharth Singh   +12 more
semanticscholar   +1 more source

JAK inhibitors in lichen planus: a review of pathogenesis and treatments

Journal of dermatological treatment (Print), 2022
Lichen planus (LP) is an auto-inflammatory skin disorder identified by a presence of T-cell lymphocytes at the dermal-epidermal junction. It is hypothesized that the INF–γ/CXCL10 axis fulfills a major role in the onset and persistence of chronic ...
Ali Motamed-Sanaye, Yasaman Fatemeh Khazaee, Motahareh Shokrgozar, M. Alishahi, Najmeh Ahramiyanpour, Maliheh Amani   +5 more
semanticscholar   +1 more source

JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases.

La Revue de medecine interne
Janus kinase (JAK) molecules are involved in important cellular activation pathways. Over the past decade, many targeted therapies have emerged, including the increasingly promising role of JAK inhibitors (JAKi) in the treatment of inflammatory and ...
L. Chikhoune, Claire Poggi, Julie Moreau, Sylvain Dubucquoi, É. Hachulla, A. Collet, David Launay   +6 more
semanticscholar   +1 more source

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.

Seminars in Arthritis & Rheumatism
OBJECTIVES The ORAL Surveillance trial, a postmarketing safety clinical trial, found an increased risk of adverse cardiovascular events and venous thromboembolism (VTE) in patients treated with Janus Kinase (JAK) inhibitors compared to tumor necrosis ...
Adam Goldman, Bat-El Lugassy Galper, Amit Druyan, C. Grossman, Kassem Sharif, L. Shechtman, Y. Moshkovits, Adi Lahat, Ilan Ben-Zvi   +8 more
semanticscholar   +1 more source